Vaso Competitors

Vaso (OTCMKTS:VASO) and Helius Medical Technologies (NASDAQ:HSDT) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, earnings, valuation, analyst recommendations, institutional ownership and profitability.

Profitability

This table compares Vaso and Helius Medical Technologies' net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of recent recommendations for Vaso and Helius Medical Technologies, as provided by MarketBeat.com.

Helius Medical Technologies has a consensus price target of $20.00, suggesting a potential upside of 11.98%. Given Helius Medical Technologies' higher probable upside, analysts plainly believe Helius Medical Technologies is more favorable than Vaso.

Valuation & Earnings

This table compares Vaso and Helius Medical Technologies' top-line revenue, earnings per share (EPS) and valuation.

Vaso has higher revenue and earnings than Helius Medical Technologies.

Volatility & Risk

Vaso has a beta of 3.26, indicating that its stock price is 226% more volatile than the S&P 500. Comparatively, Helius Medical Technologies has a beta of 0.72, indicating that its stock price is 28% less volatile than the S&P 500.

Summary

Vaso beats Helius Medical Technologies on 7 of the 10 factors compared between the two stocks.

Fc Global Realty (OTCMKTS:FCRE) and Vaso (OTCMKTS:VASO) are both small-cap computer and technology companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, earnings, analyst recommendations, institutional ownership and profitability.

Profitability

This table compares Fc Global Realty and Vaso's net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Fc Global Realty and Vaso, as provided by MarketBeat.

Valuation and Earnings

This table compares Fc Global Realty and Vaso's top-line revenue, earnings per share (EPS) and valuation.

Vaso has higher revenue and earnings than Fc Global Realty.

Volatility and Risk

Fc Global Realty has a beta of 2.31, indicating that its stock price is 131% more volatile than the S&P 500. Comparatively, Vaso has a beta of 3.26, indicating that its stock price is 226% more volatile than the S&P 500.

Summary

Vaso beats Fc Global Realty on 6 of the 7 factors compared between the two stocks.

Vaso (OTCMKTS:VASO) and Viveve Medical (NASDAQ:VIVE) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation and analyst recommendations.

Valuation & Earnings

This table compares Vaso and Viveve Medical's gross revenue, earnings per share and valuation.

Vaso has higher revenue and earnings than Viveve Medical.

Profitability

This table compares Vaso and Viveve Medical's net margins, return on equity and return on assets.

Institutional and Insider Ownership

18.2% of Viveve Medical shares are owned by institutional investors. 44.0% of Vaso shares are owned by company insiders. Comparatively, 5.0% of Viveve Medical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Vaso and Viveve Medical, as provided by MarketBeat.com.

Volatility & Risk

Vaso has a beta of 3.26, indicating that its share price is 226% more volatile than the S&P 500. Comparatively, Viveve Medical has a beta of 0.59, indicating that its share price is 41% less volatile than the S&P 500.

Summary

Vaso beats Viveve Medical on 8 of the 11 factors compared between the two stocks.

Vaso (OTCMKTS:VASO) and CHF Solutions (NASDAQ:CHFS) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, earnings, valuation, profitability, dividends, institutional ownership and analyst recommendations.

Profitability

This table compares Vaso and CHF Solutions' net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent ratings and price targets for Vaso and CHF Solutions, as provided by MarketBeat.

CHF Solutions has a consensus target price of $20.00, suggesting a potential upside of 270.37%. Given CHF Solutions' higher probable upside, analysts plainly believe CHF Solutions is more favorable than Vaso.

Valuation and Earnings

This table compares Vaso and CHF Solutions' gross revenue, earnings per share and valuation.

Vaso has higher revenue and earnings than CHF Solutions.

Institutional & Insider Ownership

65.1% of CHF Solutions shares are owned by institutional investors. 44.0% of Vaso shares are owned by company insiders. Comparatively, 0.6% of CHF Solutions shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Risk and Volatility

Vaso has a beta of 3.26, indicating that its stock price is 226% more volatile than the S&P 500. Comparatively, CHF Solutions has a beta of 1.55, indicating that its stock price is 55% more volatile than the S&P 500.

Summary

Vaso beats CHF Solutions on 8 of the 12 factors compared between the two stocks.

ReShape Lifesciences (OTCMKTS:RSLS) and Vaso (OTCMKTS:VASO) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, institutional ownership, earnings, profitability, risk and analyst recommendations.

Analyst Ratings

This is a breakdown of current ratings for ReShape Lifesciences and Vaso, as reported by MarketBeat.

Profitability

This table compares ReShape Lifesciences and Vaso's net margins, return on equity and return on assets.

Volatility and Risk

ReShape Lifesciences has a beta of 2.03, indicating that its share price is 103% more volatile than the S&P 500. Comparatively, Vaso has a beta of 3.26, indicating that its share price is 226% more volatile than the S&P 500.

Valuation and Earnings

This table compares ReShape Lifesciences and Vaso's revenue, earnings per share and valuation.

Vaso has higher revenue and earnings than ReShape Lifesciences.

Summary

Vaso beats ReShape Lifesciences on 6 of the 8 factors compared between the two stocks.

Vaso (OTCMKTS:VASO) and Precision Optics (OTCMKTS:PEYE) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, earnings, institutional ownership, valuation and risk.

Analyst Ratings

This is a summary of recent ratings and price targets for Vaso and Precision Optics, as provided by MarketBeat.

Profitability

This table compares Vaso and Precision Optics' net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Vaso and Precision Optics' top-line revenue, earnings per share (EPS) and valuation.

Vaso has higher revenue and earnings than Precision Optics.

Risk and Volatility

Vaso has a beta of 3.26, indicating that its stock price is 226% more volatile than the S&P 500. Comparatively, Precision Optics has a beta of 0.68, indicating that its stock price is 32% less volatile than the S&P 500.

Summary

Vaso beats Precision Optics on 7 of the 8 factors compared between the two stocks.